<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9607835</journal-id>
<journal-id journal-id-type="pubmed-jr-id">20545</journal-id>
<journal-id journal-id-type="nlm-ta">Mol Psychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol. Psychiatry</journal-id>
<journal-title-group>
<journal-title>Molecular psychiatry</journal-title>
</journal-title-group>
<issn pub-type="ppub">1359-4184</issn>
<issn pub-type="epub">1476-5578</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28761081</article-id>
<article-id pub-id-type="pmc">5935262</article-id>
<article-id pub-id-type="doi">10.1038/mp.2017.161</article-id>
<article-id pub-id-type="manuscript">NIHMS960801</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A neurogenetic model for the study of schizophrenia spectrum disorders: the International 22q11.2 Deletion Syndrome Brain Behavior Consortium</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Gur</surname>
<given-names>RE</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN2">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bassett</surname>
<given-names>AS</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="author-notes" rid="FN2">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McDonald-McGinn</surname>
<given-names>DM</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bearden</surname>
<given-names>CE</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chow</surname>
<given-names>E</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Emanuel</surname>
<given-names>BS</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Owen</surname>
<given-names>M</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Swillen</surname>
<given-names>A</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Van den Bree</surname>
<given-names>M</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vermeesch</surname>
<given-names>J</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vorstman</surname>
<given-names>JAS</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Warren</surname>
<given-names>S</given-names>
</name>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lehner</surname>
<given-names>T</given-names>
</name>
<xref ref-type="aff" rid="A9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Morrow</surname>
<given-names>B</given-names>
</name>
<xref ref-type="aff" rid="A10">10</xref>
</contrib>
<contrib contrib-type="author">
<collab>The International 22q11.2 Deletion Syndrome Brain Behavior Consortium</collab>
<xref ref-type="author-notes" rid="FN3">12</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Perelman School of Medicine and Children’s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA</aff>
<aff id="A2">
<label>2</label>Centre for Addiction and Mental Health, Toronto General Hospital and the University of Toronto, Toronto, ON, Canada</aff>
<aff id="A3">
<label>3</label>The Children’s Hospital of Philadelphia and the Perelman School of Medicine, University of Pennsylvania, Pennsylvania, PA, USA</aff>
<aff id="A4">
<label>4</label>University of California Los Angeles, Los Angeles, CA, USA</aff>
<aff id="A5">
<label>5</label>Cardiff University, Cardiff, UK</aff>
<aff id="A6">
<label>6</label>Katholieke University, Leuven, Belgium</aff>
<aff id="A7">
<label>7</label>Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands</aff>
<aff id="A8">
<label>8</label>Emory University, Atlanta, GA, USA</aff>
<aff id="A9">
<label>9</label>National Institute of Mental Health, Bethesda, MD, USA</aff>
<aff id="A10">
<label>10</label>Albert Einstein College of Medicine, New York, NY, USA</aff>
<author-notes>
<corresp id="FN1">Correspondence: Professor RE Gur, Department of Psychiatry, University of Pennsylvania, 10th Floor Gates Building, 3400 Spruce, Philadelphia, PA 19104, USA or Dr AS Bassett, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, ON M5S 2S1, Canada., <email>Raquel@upenn.edu</email> or <email>anne.bassett@utoronto.ca</email></corresp>
<fn fn-type="equal" id="FN2">
<label>11</label>
<p>These authors contributed equally to this work.</p>
</fn>
<fn id="FN3">
<label>12</label>
<p>List of other members of The International 22q11.2 Deletion Syndrome Brain Behavior Consortium is provided in the <xref ref-type="supplementary-material" rid="SD1">Supplemental Material</xref>.</p>
</fn>
<fn fn-type="COI-statement" id="FN4">
<p>
<bold>CONFLICT OF INTEREST</bold>
</p>
<p>DMM-M has given lectures on 22q11DS for Natera; CA has been a consultant to or has received honoraria or grants from Abbot, AMGEN, AstraZeneca, CIBERSAM, Dainippon Sumitomo Pharma, Fundación Alicia Koplowitz, Forum, Instituto de Salud Carlos III, Gedeon Richter, Janssen Cilag, Lundbeck, Ministerio de Ciencia e Innovación, Ministerio de Sanidad, Ministerio de Economía y Competitividad, Mutua Madrileña, Otsuka, Pfizer, Roche, Servier, Shire, Schering Plough, Sunovio and Takeda. DF has been a consultant and/or advisor to or has received honoraria from AstraZeneca, Bristol-Myers Squibb, Eisai, Janssen, Lundbeck, Otsuka and Ministerio de Ciencia e Innovación, Ministerio de Sanidad, Ministerio de Economía. The other authors declare no conflict of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>18</day>
<month>4</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>01</day>
<month>8</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>12</month>
<year>2018</year>
</pub-date>
<volume>22</volume>
<issue>12</issue>
<fpage>1664</fpage>
<lpage>1672</lpage>
<!--elocation-id from pubmed: 10.1038/mp.2017.161-->
<abstract>
<p id="P1">Rare copy number variants contribute significantly to the risk for schizophrenia, with the 22q11.2 locus consistently implicated. Individuals with the 22q11.2 deletion syndrome (22q11DS) have an estimated 25-fold increased risk for schizophrenia spectrum disorders, compared to individuals in the general population. The International 22q11DS Brain Behavior Consortium is examining this highly informative neurogenetic syndrome phenotypically and genomically. Here we detail the procedures of the effort to characterize the neuropsychiatric and neurobehavioral phenotypes associated with 22q11DS, focusing on schizophrenia and subthreshold expression of psychosis. The genomic approach includes a combination of whole-genome sequencing and genome-wide microarray technologies, allowing the investigation of all possible DNA variation and gene pathways influencing the schizophrenia-relevant phenotypic expression. A phenotypically rich data set provides a psychiatrically well-characterized sample of unprecedented size (<italic>n</italic> = 1616) that informs the neurobehavioral developmental course of 22q11DS. This combined set of phenotypic and genomic data will enable hypothesis testing to elucidate the mechanisms underlying the pathogenesis of schizophrenia spectrum disorders.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>